Maravai Lifesciences Holdings, Inc. Stock Price, News & Analysis

Maravai LifeSciences, Inc. (NASDAQ: MRVI) is set to release its first quarter 2023 financial and operating results on May 8, 2023, after market close. A conference call is scheduled for the same day at 2:00 p.m. PT / 5:00 p.m. ET. Investors can participate by calling (800) 715-9871 or (646) 307-1963 and referring to Conference ID 9951216. The call will also be available via live or archived webcast on the Investors section of Maravai's website.

Maravai is a prominent life sciences company that provides essential products facilitating the development of drug therapies, diagnostics, and vaccines. The company supports leading biopharmaceutical, vaccine, diagnostics, and gene therapy organizations.

Maravai LifeSciences (NASDAQ: MRVI) announced its participation in two investor conferences in March 2023. The Chief Financial Officer, Kevin Herde, and Vice President, Deborah Barbara, will engage in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2023, at 2:00 p.m. PST. Additionally, Carl Hull, Chairman of the Board and Interim CEO, will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum on March 21, 2023, at 9:45 a.m. PST. Interested parties can access a live webcast and archived presentations through the Maravai Investor Relations website.

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) reported a 10.4% decrease in fourth-quarter revenue of $204.7 million compared to the previous year, driven by a 11% decline in Nucleic Acid Production revenue. Annual revenue increased 10.5% to $883.0 million, with significant contributions from COVID-19 related CleanCap revenues. The company announced the acquisition of Alphazyme, LLC to enhance its enzyme manufacturing capabilities. For 2023, Maravai provided revenue guidance between $420 million to $460 million, projecting over 20% growth in base business revenues. Net income for the fourth quarter was $87.4 million, down from $127.1 million last year.

Maravai LifeSciences, Inc. (NASDAQ: MRVI) is set to release its fourth quarter and full year 2022 financial results on February 22, 2023. The announcement will occur after the market closes, followed by a conference call at 2:00 p.m. PT/5:00 p.m. ET. Investors can join the call via telephone or through a live and archived webcast available on the company’s investor website. As a leading provider of life science reagents, Maravai supports research and development in drug therapies, diagnostics, and vaccines, catering to top biopharmaceutical and gene therapy firms.

Maravai LifeSciences has announced the appointment of William “Trey” Martin, III as President of its Biologics Safety Testing Segment starting December 5, 2022. He is expected to become the company’s CEO on July 27, 2023. Previously, Martin was placed on paid leave due to a lawsuit concerning a noncompetition agreement but has reached a confidential settlement. Christine Dolan will continue as COO reporting to Martin, while Carl Hull remains Executive Chairman and Interim CEO. The company emphasizes confidence in Martin’s leadership amidst these transitions.